Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab.

"igg immunoglobulin g; mimoga monitoring of immune responses following mogamulizumab-containing treatment in patients with adult t-cell leukaemia-lymphoma; pbmc peripheral blood mononuclear cells [colour figure can be viewed at wileyonlinelibrary com ] the details are available in data s1 .; the details are available in data s1 .; the details are available in data s1 .; data s1."

"Conflicts of interest KN has received consultancy fees, research funding and honoraria from Kyowa Kirin, research funding from Chugai Pharmaceutical, and honoraria from Celgene, Eisai, Meiji Seika Pharma, Janssen Pharmaceutical and Bristol Myers Squibb. SK has received consultancy fees, research funding and honoraria from Chugai Pharmaceutical, research funding and honoraria from Kyowa Kirin, Daiichi Sankyo, Takeda Pharmaceutical, Janssen Pharmaceutical and honoraria from Otsuka Pharmaceutical and Eisai. NN has received consultancy fees from JIMRO and honoraria from Novartis, Takeda Pharmaceutical, Chugai Pharmaceutical, Celgene, Otsuka Pharmaceutical, Nippon Shinyaku, Kyowa Kirin and Asahi Kasei Pharma. IC has no conflicts of interest to disclose. MY has received honoraria from Novartis International, Takeda Pharmaceutical, Sanofi, Otsuka and Chugai Pharmaceutical. YI has received honoraria from Kyowa Kirin, Celgene, Eisai, Bristol Myers Squibb and Sanofi. MH has received research funding from Chugai Pharmaceutical and honoraria from Nippon Shinyaku and Symbio Pharma., KY has received honoraria from Abbvie, Amgen, Celgene, Daiichi Sankyo, Eli Lilly Japan, Janssen Pharmaceutical, Kaken Pharmaceutical, Kyowa Kirin, Maruho, Minophagen Pharmaceutical, Novartis, Sanofi, Taiho Pharmaceutical, Torii Pharmaceutical, UCB Japan, Eisai, Sun Pharma Japan. HT has received honoraria from Ono Pharmaceutical, Chugai Pharmaceutical, Eisai, Novartis International and patients, and royalties from Mesoblast. YS has received research funding and honoraria from Kyowa Kirin and honoraria from Celgene and Bristol Myers Squibb., KI has received research funding and honoraria from Kyowa Kirin. SI has received research funding and honoraria from Takeda Pharmaceutical, Ono Pharmaceutical, Janssen Pharmaceutical, Sanofi, Celgene, and research funding from Chugai Pharmaceutical, Bristol Myers Squibb, Abbvie and Daiichi Sankyo. TM is an employee of Repertoire Genesis Incorporation. AU has received honoraria from Novartis International, Kyowa Kirin, Daiichi Sankyo, Bristol Myers Squibb, Celgene, Pfizer, Minophagen Pharmaceutical, Janssen Pharmaceutical, Chugai Pharmaceutical, HUYA Japan, JIMRO, Meiji Seika Pharma and Otsuka Medical Devices. RU has received research funding from Kyowa Kirin, Chugai Pharmaceutical and Ono Pharmaceutical. HS, JM, EO, TJ, MO, AI, TaK, ToK, and TI have no conflicts of interest to disclose."

"Funding information This work was supported by a grant‐in‐aid for scientific research (C) (21K08374 to KN), and by grants‐in‐aid from the Japan Agency for Medical Research and Development (No. 20ae0101074h0001 and 21ae0101074h0001 to RU, and No. 20cm0106301h0005 and 21cm0106301h0005 to TI)."